|
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.ss) DCF Avaliação
CN | Healthcare | Biotechnology | SHH
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) Bundle
Descubra o verdadeiro valor da Shanghai Allist Pharmaceuticals Co., Ltd. (688578Ss) com nossa calculadora DCF avançada! Ajuste as principais suposições, explore vários cenários e avalie como as mudanças afetam a avaliação da Shanghai Allist Pharmaceuticals Co., Ltd. (688578Ss) - tudo dentro de um único modelo do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .6 | .6 | 530.1 | 791.0 | 2,018.2 | 3,220.5 | 5,138.9 | 8,200.3 | 13,085.4 | 20,880.7 |
| Revenue Growth, % | 0 | -10.93 | 94409.97 | 49.22 | 155.14 | 59.57 | 59.57 | 59.57 | 59.57 | 59.57 |
| EBITDA | -380.2 | -296.8 | 44.6 | 153.4 | 696.6 | -886.7 | -1,415.0 | -2,257.9 | -3,603.0 | -5,749.4 |
| EBITDA, % | -60367.94 | -52920.9 | 8.42 | 19.39 | 34.52 | -27.53 | -27.53 | -27.53 | -27.53 | -27.53 |
| Depreciation | 9.5 | 12.5 | 25.7 | 27.0 | 40.2 | 1,354.3 | 2,161.0 | 3,448.4 | 5,502.6 | 8,780.7 |
| Depreciation, % | 1514.41 | 2227.88 | 4.85 | 3.42 | 1.99 | 42.05 | 42.05 | 42.05 | 42.05 | 42.05 |
| EBIT | -389.7 | -309.3 | 18.9 | 126.4 | 656.4 | -952.8 | -1,520.4 | -2,426.2 | -3,871.5 | -6,177.8 |
| EBIT, % | -61882.35 | -55148.78 | 3.57 | 15.97 | 32.53 | -29.59 | -29.59 | -29.59 | -29.59 | -29.59 |
| Total Cash | 947.0 | 2,591.3 | 2,240.0 | 2,037.3 | 2,281.7 | 3,220.5 | 5,138.9 | 8,200.3 | 13,085.4 | 20,880.7 |
| Total Cash, percent | .2 | .5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.9 | .3 | 14.8 | 150.9 | 260.2 | 1,198.1 | 1,911.9 | 3,050.8 | 4,868.2 | 7,768.3 |
| Account Receivables, % | 294.4 | 51.26 | 2.8 | 19.07 | 12.89 | 37.2 | 37.2 | 37.2 | 37.2 | 37.2 |
| Inventories | .3 | 10.8 | 20.8 | 32.1 | 62.9 | 973.5 | 1,553.4 | 2,478.7 | 3,955.4 | 6,311.6 |
| Inventories, % | 40.04 | 1922.46 | 3.92 | 4.05 | 3.12 | 30.23 | 30.23 | 30.23 | 30.23 | 30.23 |
| Accounts Payable | 17.9 | 2.9 | 32.3 | 43.7 | 53.5 | 1,380.1 | 2,202.2 | 3,514.1 | 5,607.5 | 8,948.0 |
| Accounts Payable, % | 2845.15 | 509.7 | 6.09 | 5.52 | 2.65 | 42.85 | 42.85 | 42.85 | 42.85 | 42.85 |
| Capital Expenditure | -89.4 | -88.5 | -192.2 | -143.8 | -67.9 | -1,660.6 | -2,649.8 | -4,228.3 | -6,747.2 | -10,766.6 |
| Capital Expenditure, % | -14191.37 | -15770.48 | -36.27 | -18.18 | -3.36 | -51.56 | -51.56 | -51.56 | -51.56 | -51.56 |
| Tax Rate, % | 1.84 | 1.84 | 1.84 | 1.84 | 1.84 | 1.84 | 1.84 | 1.84 | 1.84 | 1.84 |
| EBITAT | -392.6 | -302.2 | 65.2 | 130.9 | 644.4 | -944.9 | -1,507.9 | -2,406.1 | -3,839.5 | -6,126.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -456.6 | -402.2 | -96.5 | -121.8 | 486.3 | -1,773.1 | -2,468.2 | -3,938.5 | -6,284.7 | -10,028.7 |
| WACC, % | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -19,035.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -10,229 | |||||||||
| Terminal Value | -208,552 | |||||||||
| Present Terminal Value | -149,358 | |||||||||
| Enterprise Value | -168,393 | |||||||||
| Net Debt | -1,860 | |||||||||
| Equity Value | -166,533 | |||||||||
| Diluted Shares Outstanding, MM | 450 | |||||||||
| Equity Value Per Share | -369.69 |
What You Will Receive
- Genuine Shanghai Allist Pharmaceuticals Data: Pre-filled financial information – covering everything from revenue to EBIT – based on actual and projected figures.
- Comprehensive Customization: Modify all key parameters (yellow cells) such as WACC, growth %, and tax rates.
- Instant Valuation Adjustments: Automatic recalculations to assess the effects of changes on Shanghai Allist Pharmaceuticals' fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth projections.
- Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Shanghai Allist Pharmaceuticals Co., Ltd. (688578SS).
- WACC Calculator: Includes a pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Assumptions: Easily modify growth projections, capital expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Shanghai Allist Pharmaceuticals Co., Ltd. (688578SS).
- Visualization Dashboard and Charts: Graphical representations encapsulate essential valuation metrics for straightforward analysis.
How It Functions
- Download: Obtain the pre-prepared Excel file containing Shanghai Allist Pharmaceuticals Co., Ltd.'s (688578SS) financial data.
- Customize: Modify forecasts for parameters such as revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Opt for Shanghai Allist Pharmaceuticals Calculator?
- Time Efficient: Skip the hassle of building a financial model from the ground up – it's ready for immediate use.
- Enhanced Accuracy: Dependable financial data and formulas minimize valuation errors.
- Completely Customizable: Adjust the model to align with your specific assumptions and forecasts.
- Simple to Analyze: Intuitive charts and outputs simplify result interpretation.
- Endorsed by Professionals: Crafted for experts who prioritize precision and functionality.
Who Should Use This Product?
- Individual Investors: Make informed decisions regarding the purchase or sale of Shanghai Allist Pharmaceuticals stock (688578SS).
- Financial Analysts: Enhance valuation processes with readily available financial models specific to Shanghai Allist Pharmaceuticals.
- Consultants: Provide clients with accurate and timely valuation insights on Shanghai Allist Pharmaceuticals (688578SS).
- Business Owners: Gain insights into how large pharmaceutical companies like Shanghai Allist Pharmaceuticals are valued to inform your own business strategies.
- Finance Students: Develop valuation skills using real-world data and cases related to Shanghai Allist Pharmaceuticals (688578SS).
Contents of the Template
- Pre-Filled Data: Contains historical financials and projections for Shanghai Allist Pharmaceuticals Co., Ltd. (688578SS).
- Discounted Cash Flow Model: An editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific worksheet dedicated to calculating WACC using customized inputs.
- Key Financial Ratios: Evaluate Shanghai Allist Pharmaceuticals' profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.